Asrar Alahmadi, MD
Medical Oncology · Columbus, OHNPI 1104244540
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 47.1% of the total. 2025 is the largest year on record at $25,191, more than ten times the $87 reported in 2019.
Across 49 payments — averaging $725.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$17K
- Astrazeneca UK Limited$5K
- Amgen$4K
- Daiichi Sankyo Inc.$3K
- Catalyst Pharmaceuticals, Inc.$2K
- Rigel Pharmaceuticals, Inc.$2K
- plus $2K from 13 others
Across 28 payments — averaging $21,428 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$148K
- Merck$106K
- Verastem, Inc.$105K
- Amgen$92K
- E.r. Squibb & Sons, L.L.C.$76K
- Genentech, Inc.$72K
What the payments were for
- Consulting fees$15,28243%
- Speaking & faculty fees$16,06545%
- Travel & lodging$2,1336%
- Food & beverage$2,0706%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 21 | $16,731 |
| Astrazeneca UK Limited | 2 | $4,800 |
| Amgen | 2 | $4,459 |
| Daiichi Sankyo Inc. | 2 | $3,083 |
| Catalyst Pharmaceuticals, Inc. | 3 | $2,219 |
| Rigel Pharmaceuticals, Inc. | 2 | $2,126 |
| Johnson & Johnson | 2 | $1,491 |
| Tempus AI, Inc | 3 | $140 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Novartis | 1 | $74 |
| Janssen Scientific Affairs, LLC | 1 | $67 |
| Genentech, Inc. | 1 | $63 |
| Genentech USA, Inc. | 1 | $46 |
| Incyte Corporation | 2 | $37 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $19 |
| Merck | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,550 in reported general payments places this provider in the 85th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 20 | $441,913 |
| AlecensaAlectinib Hcl | 13 | $200,678 |
| Prochlorperazine Maleate | 19 | $329 |
| Dexamethasone | 22 | $151 |
| Prednisone | 12 | $52 |
| Omeprazole | 13 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Alecensa | $46 | $200,67813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 157 medical oncology providers in Ohio.
Other medical oncology in Columbus
- David CarboneColumbus$438K
- Christian RolfoColumbus$227K
- Timothy MooreColumbus$213K
- Maryam LustbergColumbus$176K
- Timothy BurnsColumbus$64K
- Kai HeColumbus$49K
- Gregory OttersonColumbus$49K
- Sagar SardesaiColumbus$45K
- John HaysColumbus$35K
- Claire VerschraegenColumbus$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.